June 2, 2020

 

Via EDGAR Transmission

 

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn:  Amy Adams

 

Re:

Kiniksa Pharmaceuticals, Ltd.

 

Registration Statement on Form S-3

 

Filed May 21, 2020

 

Registration No. 333- 238585

 

Dear Ms. Adams:

 

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request the acceleration of the effective date of the above-referenced Registration Statement so that it will become effective on June 4, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as practicable, or at such later time as Kiniksa Pharmaceuticals, Ltd. (the “Company”) or its counsel may request via telephone call to the staff.  Please contact Nathan Ajiashvili at Latham & Watkins LLP, counsel to the Company, at (212) 906-2916, or in his absence, Salvatore Vanchieri at (212) 906-4605, to provide notice of effectiveness, or if you have any other questions or concerns regarding this matter.

 

 

Clarendon House | 2 Church Street Hamilton | HM11 Bermuda

Telephone: 808.451.3453

www.kiniksa.com

 


 

 

 

Very truly yours,

 

 

 

 

 

KINIKSA PHARMACEUTICALS, LTD.

 

 

 

 

 

 

 

 

/s/ Thomas Beetham

 

 

Thomas Beetham

 

 

 

 

 

 

cc:

Johan V. Brigham, Latham & Watkins LLP

 

 

 

Nathan Ajiashvili, Latham & Watkins LLP